Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1979 Jan;35(1):107–111.

Possible C1q bypass loop activation in the haemolytic uraemic syndrome.

L Nolin, S O'Regan, M Pelletier, G E Rivard, J G Mongeau, P Robitaille
PMCID: PMC1537596  PMID: 371879

Abstract

Ultrastructural and immunofluorescent microscopic studies were performed on renal tissue obtained from nine patients during the acute and convalescent phase of the haemolytic uraemic syndrome (HUS). All had glomerular deposits of IgM in the absence of circulating immune complexes. This was associated with deposition of C1q during the acute phase, and properdin and C3 during the convalescent phase. C4 was consistently absent. Since such a pattern of complement deposition does not fulfil criteria either for alternate or classical pathway activation, the possibility of C1q bypass loop activation by IgM is suggested.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cossio P. M., Laguens R. P., Pantin D. J., de Bracco M. M., Molinas F., Voyer L. E., Arana R. M. Persistent glomerulonephritis following the haemolytic-uremic syndrome. Immunopathological and morphological studies. Clin Exp Immunol. 1977 Sep;29(3):361–368. [PMC free article] [PubMed] [Google Scholar]
  2. Cuatrecasas P., Wilchek M., Anfinsen C. B. Selective enzyme purification by affinity chromatography. Proc Natl Acad Sci U S A. 1968 Oct;61(2):636–643. doi: 10.1073/pnas.61.2.636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. GASSER C., GAUTIER E., STECK A., SIEBENMANN R. E., OECHSLIN R. Hämolytisch-urämische Syndrome: bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr. 1955 Sep 20;85(38-39):905–909. [PubMed] [Google Scholar]
  4. Gervais M., Richardson J. B., Chiu J., Drummond K. N. Immunofluorescent and histologic findings in the hemolytic uremic syndrome. Pediatrics. 1971 Feb;47(2):352–359. [PubMed] [Google Scholar]
  5. HUNTER W. M., GREENWOOD F. C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. doi: 10.1038/194495a0. [DOI] [PubMed] [Google Scholar]
  6. Habib R., Courtecuisse V., Leclerc F., Mathieu H., Royer P. Etude anatomo-pathologique de 35 observations de syndrome hémolytique et urémique de l'enfant. Arch Fr Pediatr. 1969 Apr;26(4):391–416. [PubMed] [Google Scholar]
  7. Hay F. C., Nineham L. J., Roitt I. M. Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase C1q. Clin Exp Immunol. 1976 Jun;24(3):396–400. [PMC free article] [PubMed] [Google Scholar]
  8. Kaplan B. S., Thomson P. D., de Chadarévian J. P. The hemolytic uremic syndrome. Pediatr Clin North Am. 1976 Nov;23(4):761–777. doi: 10.1016/s0031-3955(16)33359-4. [DOI] [PubMed] [Google Scholar]
  9. Kim Y., Miller K., Michael A. F. Breakdown products of C3 and factor B in hemolytic-uremic syndrome. J Lab Clin Med. 1977 Apr;89(4):845–850. [PubMed] [Google Scholar]
  10. Klein P. J., Bulla M., Newman R. A., Müller P., Uhlenbruck G., Schaefer H. E., Krüger G., Fisher R. Thomsen-Friedenreich antigen in haemolytic-uraemic syndrome. Lancet. 1977 Nov 12;2(8046):1024–1025. doi: 10.1016/s0140-6736(77)92915-4. [DOI] [PubMed] [Google Scholar]
  11. May J. E., Frank M. M. A new complement-mediated cytolytic mechanism--the C1-bypass activation pathway. Proc Natl Acad Sci U S A. 1973 Mar;70(3):649–652. doi: 10.1073/pnas.70.3.649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. van Wieringen P. M., Monnens L. A., Bakkeren J. A. Hemolytic-uremic syndrome: absence of circulating endotoxin. Pediatrics. 1976 Oct;58(4):561–563. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES